May 14, 2025 04:27PM scPharmaceuticals Inc. (SCPH) Misses Q1 EPS by 4c

Mar 19, 2025 04:19PM scPharmaceuticals Inc. (SCPH) Tops Q4 EPS by 3c

Mar 7, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on scPharmaceuticals (SCPH)

Mar 6, 2025 04:01PM scPharmaceuticals (SCPH) Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

Jan 10, 2025 08:07AM scPharmaceuticals (SCPH) Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Dec 2, 2024 09:39AM scPharmaceuticals (SCPH) PT Lowered to $13 at Jefferies

Nov 13, 2024 05:19PM scPharmaceuticals Inc. (SCPH) Misses Q3 EPS by 45c

Oct 23, 2024 08:11AM TD Cowen Reiterates Buy Rating on scPharmaceuticals (SCPH)

Aug 19, 2024 06:50AM H.C. Wainwright Reiterates Buy Rating on scPharmaceuticals (SCPH)

Aug 14, 2024 04:05PM scPharmaceuticals Inc. (SCPH) Misses Q2 EPS by 3c

Aug 13, 2024 09:58AM TD Cowen Reiterates Buy Rating on scPharmaceuticals (SCPH)

Aug 12, 2024 09:50AM scPharmaceuticals (SCPH) Prices 12M Share Offering at $4/sh

Aug 12, 2024 06:05AM scPharmaceuticals (SCPH) Announces Up to $125M Non-Dilutive Financings

Aug 12, 2024 06:04AM scPharmaceuticals (SCPH) Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication

Aug 12, 2024 06:02AM scPharmaceuticals (SCPH) Reports Positive Topline Study Results for SCP-111

Aug 12, 2024 06:02AM scPharmaceuticals (SCPH) Announces Proposed Share Offering

Jul 25, 2024 08:02AM scPharmaceuticals (SCPH) Announces Filing Acceptance of sNDA Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease